1. Healx, an AI-enabled drug discovery platform focused on rare diseases, has raised $47 million in a Series B funding round. The company's platform leverages artificial intelligence and machine learning to accelerate the drug discovery process for rare diseases, which often lack effective treatments due to the small patient populations and limited commercial incentives for traditional pharmaceutical companies.

2. Healx's approach combines AI-powered drug discovery with a patient-centric model, working closely with patient organizations and disease experts to identify unmet needs and develop tailored treatments. The company has already identified promising drug candidates for several rare diseases and is currently conducting clinical trials for its lead program targeting Fragile X syndrome, a genetic condition that causes intellectual disability and autism.

3. The new funding will enable Healx to expand its AI platform, advance its pipeline of rare disease programs, and further strengthen its collaborations with patient groups, academic institutions, and pharmaceutical partners. The company's success highlights the growing potential of AI-driven drug discovery to address the challenges faced in developing treatments for rare and neglected diseases, which often lack the commercial incentives for traditional pharmaceutical companies.